Generic Industry’s Perspective on the New GMP Initiative 2002 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance TEVA.

Slides:

Advertisements

Similar presentations

FDA’s Proposed Rule under FSMA for Preventive Controls

Advertisements

Audit of IT Systems SARQA / DKG Scandinavian Conference, October 2002, Copenhagen Sue Gregory.

Florida Pilot Initiative for the Performance Approach to Measurement Systems Stephen Arms Florida Department of Health.

VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.

Intentional Adulteration Phase 2 Workgroup 1.

Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practices (GMPs): The Big Picture of a Long-term Commitment Elizabeth Pollina Cormier,

What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.

Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.

Industry Coalition on 21 CFR Part 11 Recommendations for Achieving Compliance with the Electronic Records and Electronic Signatures Regulation.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

Education and Technical Assistance Focus on Preventive Controls for Food for Animals U.S. Food and Drug Administration.

Radiopharmaceutical Production

Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum 21 CFR Part 11 Considerations November 14, 2002.

Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.

Regulatory requirements and benefits converting to Continued Process Verification.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Validation perceptions that may slow PAT development and implementation Steve Hammond Pfizer Global Manufacturing.

21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.

VALIDATION & PERSONNEL

Ed Hudson, Systemwide Director, Information Security Gina Curry, Director, Student Financial Services Center & University Bursar, CSU Sacramento.

Quality By Design - A Generic Industry Perspective

Regulatory Update Ellen Leinfuss SVP, Life Sciences.

Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.

PERSONNEL TRAINING IN BIOANALYSIS DR. SHIVPRAKASH MANAGING DIRECTOR SYNCHRON RESEARCH SERVICES PVT. LTD., INDIA.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.

Good Practices in Production and Quality Control Related Guidelines

The Process of Creating a Strategic Plan Tessa Dixon Program Administrator DHH/OPH/Specialty Operations/Food & Drug Unit March 12, :00 – 10:00 am.

Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,

Module 1,, Part 5: Review and summary Slide 1 of 13 © WHO – EDM Validation Part 5: Review and summary Supplementary Training Modules on Good Manufacturing.

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

Molecule-to-Market-Place Quality

Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.

Generic Industry’s Perspective on the New GMP Initiative May 21, 2003 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

The world leader in serving science Validation and Qualification Overview Mike Garry Software Product Manager Spectroscopy Software Platform Team.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.

Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Pharmaceutical Quality Control & current Good Manufacturing Practice

Where Are We Now With Implementation March 11, :00 – 8:45 am Ellen Buchanan Director U.S. FDA Office of Regulatory Affairs, Office of Operations,

Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Current MFRPS State Implementation Status February 3, :15 – 9:45 am Timothy Weigner Staff Director U.S. FDA Office of Regulatory Affairs, Office.

Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Webinar On Transfer of Analytical Methods.

© Pharmaceutical Consultancy Services, All rights reserved. Quality System(s) Jaap Koster.

November 6, 2013 Purchasing Controls & Supplier Quality Best Practices Beyond Compliance for the Medical Device Industry AdvaMed 2013 Bernie Liebler Technology.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

INDIANA AGRICULTURE Grow With Us!.

Track 11 Symposium 27 June :30 – 3:00 PM

Pharmaceutical Quality Control & current Good Manufacturing Practice

Department of Water and Environmental Regulation

MHRA GMP Inspection Deficiency Data Trend 2016

FSMA Implementation Jennifer Thomas

The Information Professional’s Role in Product Safety

Industrial Pharmacy.

Lesson 5: BRITE Seminar: GMP II

PhUSE Computational Science

Industrial Training Provider ,

Developing an Effective Compliance Training Program for Pharmaceutical Sales Personnel Kelly B. Freeman, Ph.D. Director, US Affiliate, Compliance and.

OECD good practices for setting up an RIA system Regional Capacity-Building Seminar on Regulatory Impact Assessment Istanbul, Turkey 20 November 2007.

Panel discussion GMP inspection process – Health Canada

Presentation transcript:

Generic Industry’s Perspective on the New GMP Initiative 2002 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance TEVA Pharmaceuticals USA

Modernization and Consistent Enforcement of cGMPs is Needed: Center and Field District to District

Best Approach: Guidance Documents Needed Examples: –Cleaning Validation –Process Validation –Training –Vendor Qualification

Cleaning Validation Levels Matrix Approach Monitoring Program

Process Validation Impact of Validation in Future Production Lessen requirements for commercial production. Unnecessary Testing.

Training Level Documentation / Tracking

Vendor Qualification Repeat of testing Reduced Testing Documentation / Rational

Summary – Guidance GPhA welcomes the opportunity to work with FDA, industry and academia on developing the science to create the procedure to allow for a new regulatory framework.